1. Introduction {#sec1-ijms-19-01117}
===============

As the advancement in drug development increases, side effects are an important concern. Among these side effects, the most frequently studied factor is nephrotoxicity \[[@B1-ijms-19-01117],[@B2-ijms-19-01117]\]. About 5% of the filtered drugs are reabsorbed actively and can reach high concentrations in the proximal tubular cells of the kidney \[[@B3-ijms-19-01117],[@B4-ijms-19-01117]\]. In this condition, the kidneys do not function properly, affecting homeostasis \[[@B5-ijms-19-01117],[@B6-ijms-19-01117]\].

Nephrotoxicity is induced by various drugs, such as acetaminophen (drug used to treat pain and fever), adriamycin, cisplatin, doxorubicin (anticancer drug), aminoglycosides, fluoroquinolones (antibiotics), and cyclosporine A (immunosuppressant) \[[@B7-ijms-19-01117],[@B8-ijms-19-01117],[@B9-ijms-19-01117]\]. Among these drugs, cisplatin, a platinum-based anticancer drug, is effective in the treatment of human cervical cancer at various stages \[[@B10-ijms-19-01117],[@B11-ijms-19-01117],[@B12-ijms-19-01117],[@B13-ijms-19-01117]\]. However, it has serious side effects that limit its usefulness. In particular, nephrotoxicity remains a major concern for anticancer chemotherapy using cisplatin \[[@B14-ijms-19-01117],[@B15-ijms-19-01117]\].

Mulberry (*Morus alba* L.) is a well-known medicinal plant (Moraceae) widely distributed in Asia, North America, South America, Europe, and Africa; mulberry trees have been cultivated in China, Korea, and Japan as their leaves are used to feed silkworms (*Bombyx mori* L.). Different parts of the mulberry tree, including its root bark, leaves, and fruits, have been used in traditional Chinese medicines. The mulberry tree has shown various pharmaceutical benefits against cancer, aging, neurological and cardiovascular diseases, inflammation, diabetes, and bacterial infections \[[@B16-ijms-19-01117],[@B17-ijms-19-01117],[@B18-ijms-19-01117]\]. Interestingly, mulberry fruits are often dried, or made into wine, juice, and jam worldwide \[[@B16-ijms-19-01117],[@B17-ijms-19-01117]\]. Studies on the pharmaceutical potential and bioactive ingredients of mulberry have been conducted \[[@B16-ijms-19-01117]\]. Mulberry has a number of bioactive compounds such as polyphenols, flavonoids, anthocyanins, and carotenoids; in particular, mulberry fruit has been reported to have various bioactive constituents, such as alkaloids, vitamins, fats (mainly linoleic acid, palmitic acid, oleic acid), and minerals \[[@B19-ijms-19-01117],[@B20-ijms-19-01117],[@B21-ijms-19-01117]\]. These compounds exhibit potential bioactivities including antioxidative, anti-inflammatory, antitumor, and antidiabetic effects, cardiovascular, hepatoprotective, neuroprotective, hypoglycemic, hypotensive, and diuretic activities \[[@B16-ijms-19-01117],[@B22-ijms-19-01117]\].

In our study of bioactive compounds from Korean medicinal plants, we investigated the bioactive constituents in mulberries and recently reported heterocyclic compounds and their antiangiogenic activities \[[@B23-ijms-19-01117]\]. In our continuing research on the investigation of bioactive metabolites from mulberry, phytochemical analysis of the mulberry fruits led to the isolation of five compounds. In the present study, we investigated the health benefits of the isolated compounds on cisplatin-induced side effects by cell-based assays. We tested all the compounds isolated from mulberry fruits for their protective effects on cisplatin-induced cytotoxicity in LLC-PK1 kidney cells and identified their mechanism of action.

2. Results and Discussion {#sec2-ijms-19-01117}
=========================

2.1. Isolation and Structural Identification of Compounds {#sec2dot1-ijms-19-01117}
---------------------------------------------------------

The fruits of *M. alba* were extracted with 70% ethanol, and this ethanolic extract was sequentially separated by solvent partitioning (hexane, CH~2~Cl~2~, EtOAc, and *n*-BuOH) to obtain four main fractions. As the *n*-BuOH-soluble fraction accounted for a substantial amount of obtained fractions and the CH~2~Cl~2~-soluble fraction was already investigated in our previous study \[[@B23-ijms-19-01117]\], phytochemical analysis was taken upon with the *n*-BuOH-soluble fraction in this study. Chemical analysis of the *n*-BuOH fraction led to the successful isolation of five compounds **1**--**5** ([Figure 1](#ijms-19-01117-f001){ref-type="fig"}) using column chromatography, preparative high-performance liquid chromatography (HPLC), and semi-preparative HPLC purification. The structures of the compounds were identified as butyl pyroglutamate (**1**) \[[@B24-ijms-19-01117]\], quercetin 3-*O*-β-[d]{.smallcaps}-glucoside (**2**) \[[@B25-ijms-19-01117]\], kaempferol 3-*O*-β-[d]{.smallcaps}-rutinoside (**3**) \[[@B26-ijms-19-01117]\], rutin (**4**) \[[@B27-ijms-19-01117]\], and 2-phenylethyl [d]{.smallcaps}-rutinoside (**5**) \[[@B28-ijms-19-01117]\] by spectroscopic data analysis, comparing their nuclear magnetic resonance (NMR) data with those in published literature, and liquid chromatography--mass spectrometry (LC/MS) analysis.

Butyl pyroglutamate (**1**) could be an artifact during isolation because compound **1** was isolated from *n*-BuOH-soluble fraction. To identify whether compound **1** was a genuine natural compound or an isolation artifact, the crude ethanolic extract of *M. alba* fruits was analyzed by LC/MS and co-injected with the pure compound **1**. In the LC/MS analysis, we found a peak with the molecular ion corresponding to compound **1** in the crude ethanolic extract at the same retention time as that of compound **1**. This suggested that compound **1** was a genuine natural compound.

2.2. Bioactivities {#sec2dot2-ijms-19-01117}
------------------

Cisplatin is effective in the treatment of cervical cancer; however, its usefulness is often limited due to its severe side effects \[[@B10-ijms-19-01117],[@B29-ijms-19-01117],[@B30-ijms-19-01117],[@B31-ijms-19-01117]\]. A major side effect in patients who have been prescribed anticancer drugs is nephrotoxicity. Cisplatin-induced nephrotoxicity is characterized by inflammation, apoptosis, or necrosis through accumulation in the organelle of epithelial tubule cells \[[@B2-ijms-19-01117],[@B32-ijms-19-01117]\].

We tested the effects of the isolated compounds on cisplatin-induced kidney cell damage. The protective effect of compounds **1**--**5** against cisplatin-induced cytotoxicity in LLC-PK1 kidney cell line was evaluated in this study. This cell line is one of the most frequently used cell-based models for evaluating cisplatin-induced nephrotoxicity \[[@B33-ijms-19-01117],[@B34-ijms-19-01117],[@B35-ijms-19-01117]\]. We performed comparative experiments with compounds **1**--**5**. The cytotoxicity of 25 μM cisplatin in LLC-PK1 cells was reversed by co-treatment with compounds **1**--**5** ([Figure 2](#ijms-19-01117-f002){ref-type="fig"}). The effect of compound **1** was the most pronounced among the five compounds.

*N*-Acetylcysteine (NAC) was used as a positive control protects against cisplatin-induced kidney cell death \[[@B36-ijms-19-01117]\]. As shown in [Figure 2](#ijms-19-01117-f002){ref-type="fig"}, compared with the positive control, compound **1** exerted more than 83.14 ± 3.15% protective effects at 10 μM. The protective effect of compound **1** was quite stronger than that of NAC. We further explored whether compound **1** could decrease cisplatin-induced apoptosis in LLC-PK1 cells through annexin V Alexa Fluor 488 and propidium iodide staining. As shown in [Figure 3](#ijms-19-01117-f003){ref-type="fig"}A, apoptotic cell death (indicated by annexin V staining) was increased by 25 μM cisplatin from 1.0 ± 0.0% to 40.3 ± 1.5%, whereas it decreased after co-treatment with compound **1** (10, 25 μM) by 19.3 ± 0.57%. The percentage of apoptotic cells is shown in the bar graph in [Figure 3](#ijms-19-01117-f003){ref-type="fig"}B. Regarding the effect of compound **1** (10 and 25 μM) on mitogen-activated protein kinase (MAPK) protein expression in cisplatin-induced apoptosis in LLC-PK1 cells, the phosphorylation of Jun N-terminal kinase (JNK), extracellular signal-regulated kinase (ERK), p38, mitogen-activated protein kinase (MAPK), and cleaved caspase-3 decreased after treatment with compound **1** (10 and 25 μM) in a concentration-dependent manner ([Figure 3](#ijms-19-01117-f003){ref-type="fig"}C).

The cisplatin-induced nephrotoxicity occurs in combination with an interconnected pathway such as oxidative stress, inflammatory, MAPK, and apoptosis pathways \[[@B31-ijms-19-01117],[@B32-ijms-19-01117]\]. MAPKs are crucial enzymes involved in various intracellular pathways, such as cell differentiation, proliferation, survival, and death. They are composed of JNK, p38, and ERK, which are detectable in various renal cells \[[@B37-ijms-19-01117]\].

JNK and p38 are induced by cellular stress, inflammatory response, and apoptotic pathways, and activated in renal ischemia--reperfusion. ERK is mostly induced by cell death and survival growth factors and activated in toxic renal injury \[[@B31-ijms-19-01117],[@B38-ijms-19-01117]\]. The apoptotic pathway in cisplatin-induced apoptosis is characterized by the loss of renal cells that provoke the dysfunction of the kidney. Cisplatin impairs the pathogenesis of nephrotoxicity through the expression of caspase-3, which plays an important role in the apoptotic pathway \[[@B39-ijms-19-01117],[@B40-ijms-19-01117]\]. In line with these studies, our results demonstrated that the phosphorylation of JNK, ERK, p38 MAP kinase, and caspase-3 was increased by cisplatin, but decreased after treatment with compound **1**, and that the percentage of apoptotic cells also decreased.

3. Materials and Methods {#sec3-ijms-19-01117}
========================

3.1. General Experimental Procedures {#sec3dot1-ijms-19-01117}
------------------------------------

Optical rotations were calculated using a Jasco P-1020 polarimeter (Jasco, Easton, MD, USA). Infra red spectra were recorded using a Bruker IFS-66/S FT-IR spectrometer (Bruker, Karlsruhe, Germany). Ultraviolet--visible (UV) spectra were obtained on an Agilent 8453 UV--visible spectrophotometer (Agilent Technologies, Milford, MA, USA). LC/MS analysis was conducted on an Agilent 1200 Series HPLC system equipped with a diode array detector and 6130 Series ESI mass spectrometer (Agilent Technologies). NMR spectra, including ^1^H--^1^H correlation spectroscopy, heteronuclear single-quantum correlation, and heteronuclear multiple bond correlation experiments, were documented using a Bruker AVANCE III 700 NMR spectrometer (Bruker, Madison, WI, USA) operating at 700 MHz (^1^H) and 175 MHz (^13^C), respectively. In preparative HPLC, we used Waters 1525 binary HPLC pump with Waters 996 photodiode array detector and Agilent Eclipse C18 column (21.2 × 250 mm; flow rate: 5 mL/min). In semi-preparative HPLC, Shimadzu Prominence HPLC System with SPD-20A/20AV Series Prominence HPLC UV--vis Detectors and Phenomenex Luna HPLC phenyl-hexyl column (250 × 10 mm; flow rate: 2 mL/min) was used. Column chromatography was performed with a silica gel 60 (Merck, Frankfurt, Germany, 230--400 mesh), RP-C18 silica gel (Merck, 230--400 mesh) and HP-20 dianion column. Merck precoated silica gel F254 plates and reversed-phase (RP)-18 F254s plates were utilized for thin-layer chromatography. Spots were detected on TLC under UV light or heated under anisaldehyde--sulfuric acid dye.

3.2. Plant Material {#sec3dot2-ijms-19-01117}
-------------------

The fruits of *M. alba* were obtained from the Kyungdong Market (Woori Herb), Seoul, Korea, in January 2014. A voucher specimen (MA 1414) of the material was confirmed by one of the authors (Ki Hyun Kim) and located in laboratory 306 of the Dong-A ST Research Center, Yongin, Korea.

3.3. Extraction and Isolation {#sec3dot3-ijms-19-01117}
-----------------------------

Dried and mashed *M. alba* fruits (9.7 kg) were extracted by mixing the material with 70% aqueous EtOH thrice at room temperature and filtered. After evaporation of the filtrate in vacuo, the resultant residue (1.4 kg) was dissolved in deionized water and solvent-partitioned with hexane, CH~2~Cl~2~, EtOAc, and *n*-BuOH (each of 800 mL × 3), which afforded 27.8, 85.3, 32.9, and 138.8 g of each fraction, respectively. The *n*-BuOH-soluble fraction (138.8 g) was subjected to a HP-20 dianion column and washed with H~2~O and MeOH to give two fractions: MeOH-soluble fraction (14.1 g) and water-soluble fraction (57.7 g). The MeOH fraction (14.1 g) was separated using a silica gel (230−400 mesh) column and CH~2~Cl~2~--MeOH--H~2~O (9:3:0.1) into five fractions (A--E). Fraction A (2.6 g) was subjected to an RP-C18 silica gel (230--400 mesh) column chromatography (elution with 40% MeOH) to obtain seven fractions (A1--A7). Fraction A6 (640 mg) was separated using preparative reversed-phase HPLC using Agilent Eclipse C18 column (21.2 × 250 mm; flow rate: 5 mL/min) and 30% MeOH into six subfractions (A61--66). Subfraction A65 (18 mg) was separated using semi-preparative reversed-phase HPLC using Phenomenex Luna HPLC phenyl-hexyl column (250 × 10 mm; flow rate: 2 mL/min) and 20% MeCN to obtain compound **1** (4.0 mg, *t*~R~ = 44.0 min). Fraction B (1.2 g) was subjected to an RP-C18 silica gel (230−400 mesh) column chromatography (elution with 10%, 30%, 50%, and 100% MeOH/H~2~O) to obtain four fractions (B1--B4). Fraction B3 (258 mg) was isolated by preparative reversed-phase HPLC using Agilent Eclipse C18 column (21.2 × 250 mm; flow rate: 5 mL/min) with 30% MeOH to obtain seven subfractions (B31--B37). Subfraction B32 (31.1 mg) was purified by semi-preparative reversed-phase HPLC using Phenomenex Luna HPLC phenyl-hexyl column (250 × 10 mm; flow rate: 2 mL/min) with 13% MeCN to furnish compound **5** (0.5 mg, *t*~R~ = 44.0 min). Subfraction B34 (18.3 mg) was purified by semi-preparative reversed-phase HPLC with 45% MeOH to yield compound **3** (5.7 mg, *t*~R~ = 40.0 min) using Phenomenex Luna HPLC phenyl-hexyl column (250 × 10 mm; flow rate: 2 mL/min). Fraction B35 (27.5 mg) was isolated with semi-preparative HPLC using Phenomenex Luna HPLC phenyl-hexyl column (250 × 10 mm; flow rate: 2 mL/min) with 30% MeOH to obtain compound **2** (5.7 mg, *t*~R~ = 34.0 min). Finally, fraction D (0.6 g) was subjected to an RP-C18 silica gel (230--400 mesh) column chromatography (elution with 50% MeOH) to obtain four subfractions (D1--D4). Subfraction D4 (80.3 mg) was also subjected to semi-preparative reversed-phase HPLC using Phenomenex Luna HPLC phenyl-hexyl column (250 × 10 mm; flow rate: 2 mL/min) with 18% MeCN to obtain compound **4** (7.0 mg, *t*~R~ = 21.5 min).

3.4. Cell Culture {#sec3dot4-ijms-19-01117}
-----------------

LLC-PK1 kidney cell line was purchased from the American Type Culture Collection (Rockville, MD, USA); cultured in Dulbecco's modified Eagle's medium (DMEM) (Cellgro, Manassas, VA, USA) supplemented with 100 units/mL penicillin, 10% FBS, and 100 μg/mL streptomycin; and cultured at 37 °C in a humidified atmosphere with 5% CO~2~.

3.5. Renoprotective Effect against Cisplatin-Induced Cytotoxicity in LLC-PK1 Kidney Cells {#sec3dot5-ijms-19-01117}
-----------------------------------------------------------------------------------------

The LLC-PK1 cells were seeded on 96-well culture plates at 1 × 10^4^ cells per well and incubated with different concentrations of compounds **1**--**5** and/or 25 μM cisplatin. After incubation for 24 h, the medium containing all the compounds was removed. Ez-Cytox reagent (10 µL) was added to each well and incubated at 37 °C for 1 h. The viability of the cells was measured using a microplate reader at an absorbance of 450 nm (PowerWave XS; Bio-Tek Instruments, Winooski, VT, USA).

3.6. Western Blot Analysis {#sec3dot6-ijms-19-01117}
--------------------------

Whole cell lysates for Western blot analysis were prepared in a lysis buffer (Cell Signaling, Danvers, MA, USA) containing 1 mM phenylmethylsulfonyl fluoride. The proteins (20 µg) were applied to electrophoresis in a pre-casted 4--15% Mini-PROTEAN TGX gel (Bio-Rad, Hercules, CA, USA) and blotted onto PVDF transfer membranes. Then, the membranes were blocked in 5% skim milk at room temperature for 1 h and analyzed with epitope-specific primary and secondary antibodies. Each antibody was detected and visualized by ECL Advance Western Blotting Detection Reagents (GE Healthcare, Amersham, UK) and a FUSION Solo Chemiluminescence System (PEQLAB Biotechnologie GmbH, Erlangen, Germany).

3.7. Statistical Analysis {#sec3dot7-ijms-19-01117}
-------------------------

The data are presented as the mean standard deviation (SD). Statistical significance was determined using Mann--Whitney U test. *p*-Values \< 0.05 were considered statistically significant.

4. Conclusions {#sec4-ijms-19-01117}
==============

In the present study, we identified five compounds in mulberry fruits. The isolated compounds **1**--**5** were evaluated for their effects on anticancer drug-induced side effects by using cell-based assays. Of the identified compounds in the mulberry fruits, compound **1**, butyl pyroglutamate, showed the most pronounced protective effect against cisplatin-induced kidney cell damage. This effect was found to be mediated by the attenuation of phosphorylation of JNK, ERK, p38 MAP kinase, and caspase-3 in cisplatin-induced kidney cell damage. The results of our study may provide basis for the development of novel protective agents that can be used in the treatment of cisplatin-induced nephrotoxicity.
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![Comparison of protective effects of compounds **1**--**5** against cisplatin-induced cytotoxicity in LLC-PK1 kidney cell line. (**A**) Effect of positive control (*N*-acetylcysteine, NAC) on cisplatin-induced cytotoxicity; (**B**) Effect of compound **1**; (**C**) Effect of compound **2** on cisplatin-induced cytotoxicity; (**D**) Effect of compound **3** on cisplatin-induced cytotoxicity; (**E**) Effect of compound **4** on cisplatin-induced cytotoxicity; (**F**) Effect of compound **5** on cisplatin-induced cytotoxicity. \* *p* \< 0.05 compared to the cisplatin-treated value.](ijms-19-01117-g002){#ijms-19-01117-f002}

![Mechanism of protective effect of compound **1** against cisplatin-induced apoptosis in LLC-PK1 kidney cells. (**A**) Representative images of apoptotic cells (magnifications of ×4); (**B**) Percentage of apoptotic cells; (**C**) Compound **1** activates the MAPK-caspase-3 pathway in LLC-PK1 kidney cell line. \* *p* \< 0.05 compared to the cisplatin-treated value.](ijms-19-01117-g003){#ijms-19-01117-f003}
